Open AccessNuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer
Author(s) -
Iwaya Keiichi,
Tsuda Hitoshi,
Hiraide Hoshio,
Tamaki Kuniyoshi,
Tamakuma Syouetsu,
Fukutomi Takashi,
Mukai Kiyoshi,
Hirohashi Setsuo
Publication year - 1991
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1991.tb02710.x
Subject(s) - breast cancer , pathology , immunohistochemistry , estrogen receptor , mammary gland , medicine , cell nucleus , cancer , monoclonal antibody , nuclear protein , cancer research , antibody , biology , oncology , immunology , transcription factor , gene , nucleus , biochemistry , psychiatry
p53 protein has been frequently detected at high levels in the nuclei of human breast cancer cells. We analyzed inununohistochemically the association between nuclear localization of p53 protein and clinical and histological parameters of breast cancer patients. Surgically resected tissues of 73 primary breast cancers were processed by acetone fixation and paraffin embedding and examined using an anti‐p53 monoclonal antibody, Pabl801. p53 immunoreactivity was detected in the nuclei of cancer cells in 17 cases (23%). The nuclear p53 immunoreaction was closely associated with overexpression of c‐ erb B‐2 protein (P<0.05), high histologic grade (P<0.01), advanced clinical stage (P<0.05), and negative estrogen receptor status (P< 0.01). When 31 cases which had been followed up for more than 50 months were examined, a positive nuclear p53 immunoreaction was found to he significantly associated with shorter overall survival of patients (P<0.01). These results suggest that inununohistochemical examination of nuclear p53 protein is clinically useful as an indicator of breast cancer aggressiveness.